Eisai, Takeda Report Losses Due to Acquisitions; Daiichi Sankyo Reports Earnings Lower Because Of NHI Drug Pricing
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Top Japanese pharmaceutical manufacturers July 31 reported mixed earnings results for their latest reporting periods, reflecting the costs of acquisitions and reductions in Japan's national health insurance drug pricing
You may also be interested in...
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion